Who should get one?
Author: Karen Weintraub, USA TODAY
Revolutionary leukemia treatment offers ‘a hopeful moment’ in fight against solid tumors
The cancer immunotherapy called CAR-T, has revolutionized the treatment of blood cancers. Doctors are now seeing signs it also may fight solid tumors.
Biden administration launches effort to better understand, support and treat disabling long COVID
Under the new plan, some long COVID sufferers may qualify for disability rights. It also focuses on research, services and insurance coverage.
Why do some people seem unable to catch COVID? Scientists are looking for answers.
Scientists are studying people intentionally exposed to the virus that causes COVID and those who don’t get sick to find out why some avoid infection.
Pfizer-BioNTech requests FDA authorization for fourth COVID vaccine shot for 65 and older
It’s not clear how long the Food and Drug Administration will take to review the request or whether it will convene its expert panel to review it.
Pfizer-BioNTech requests FDA authorization for fourth COVID vaccine shot for 65 and older
It’s not clear how long the Food and Drug Administration will take to review the request or whether it will convene its expert panel to review it.
Paul Farmer, a global health pioneer and the world’s ‘most extraordinary medical humanitarian,’ dies at 62
Dr. Paul Farmer, a professor at Harvard Medical School and co-founder of the nonprofit Partners In Health, died Monday in Rwanda.
Just how bad is it to be in ICU with COVID? Far more miserable than people realize, experts say
Weeks of sedation, months of rehab and perhaps years of lingering symptoms is typical for people who have ended up in an ICU because of COVID.
Omicron’s new variant cousin, BA.2, has arrived in the US. But don’t panic yet, experts say.
Cases of omicron BA.2 have been reported in at least four states – California, New Mexico, Texas and Washington – and on three other continents.
Pfizer and BioNTech announce plans to test omicron-specific COVID-19 vaccine in adult trials
Pfizer and BioNTech will conduct three simultaneous trials in adults to determine if an omicron-specific vaccine is more effective than current shots.